1. Home
  2. VGI vs TENX Comparison

VGI vs TENX Comparison

Compare VGI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Global Multi-Sector Income Fund of Beneficial Interest

VGI

Virtus Global Multi-Sector Income Fund of Beneficial Interest

N/A

Current Price

$7.29

Market Cap

82.6M

Sector

Finance

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$1.74

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGI
TENX
Founded
2012
1967
Country
United States
United States
Employees
N/A
16
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.6M
71.1M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
VGI
TENX
Price
$7.29
$1.74
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
39.7K
8.0M
Earning Date
01-01-0001
05-15-2026
Dividend Yield
12.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.18
$1.31
52 Week High
$8.09
$19.40

Technical Indicators

Market Signals
Indicator
VGI
TENX
Relative Strength Index (RSI) 44.57 19.00
Support Level $7.23 $1.31
Resistance Level $7.92 $16.39
Average True Range (ATR) 0.07 0.45
MACD -0.00 -0.59
Stochastic Oscillator 25.00 3.34

Price Performance

Historical Comparison
VGI
TENX

About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest

Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: